{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T12:13:02Z","timestamp":1779970382367,"version":"3.53.1"},"reference-count":270,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T00:00:00Z","timestamp":1659139200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.biopha.2022.113499","type":"journal-article","created":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T04:24:42Z","timestamp":1659414282000},"page":"113499","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["A comprehensive insight into current control of COVID-19: Immunogenicity, vaccination, and treatment."],"prefix":"10.1016","volume":"153","author":[{"given":"Yasser","family":"Mohamed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousra A.","family":"El-Maradny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed K.","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AbdElAziz A.","family":"Nayl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamada","family":"El-Gendi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esmail M.","family":"El-Fakharany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2022.113499_bib1","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding","volume":"395","author":"Lu","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2022.113499_bib2","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/1471-2334-6-130","article-title":"How long do nosocomial pathogens persist on inanimate surfaces? A systematic review","volume":"6","author":"Kramer","year":"2006","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.biopha.2022.113499_bib3","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","volume":"395","author":"Chen","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2022.113499_bib4","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ijid.2020.01.050","article-title":"Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: A data-driven analysis in the early phase of the outbreak","volume":"92","author":"Zhao","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.biopha.2022.113499_bib5","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding","volume":"395","author":"Lu","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2022.113499_bib6","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00127-20","article-title":"Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus","volume":"94","author":"Wan","year":"2020","journal-title":"J. Virol."},{"key":"10.1016\/j.biopha.2022.113499_bib7","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2022.113499_bib8","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.coviro.2012.04.004","article-title":"SARS coronavirus pathogenesis: host innate immune responses and viral antagonism of interferon","volume":"2","author":"Totura","year":"2012","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.biopha.2022.113499_bib9","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2022.113499_bib10","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","volume":"395","author":"Chen","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2022.113499_bib11","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1080\/08830185.2020.1844195","article-title":"Dendritic cells in COVID-19 immunopathogenesis: insights for a possible role in determining disease outcome","volume":"40","author":"Borges","year":"2021","journal-title":"Int Rev. Immunol."},{"key":"10.1016\/j.biopha.2022.113499_bib12","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1056\/NEJMp2005630","article-title":"Developing Covid-19 vaccines at pandemic speed","volume":"382","author":"Lurie","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2022.113499_bib13","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2026207118","article-title":"Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination","volume":"118","author":"Tscherne","year":"2021","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.biopha.2022.113499_bib14","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/S0140-6736(20)30304-4","article-title":"Baricitinib as potential treatment for 2019-nCoV acute respiratory disease","volume":"395","author":"Richardson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2022.113499_bib15","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/nri.2017.138","article-title":"Tissue-specific immunopathology during malaria infection","volume":"18","author":"Coban","year":"2018","journal-title":"Nat. Rev. Immunol."},{"issue":"2004","key":"10.1016\/j.biopha.2022.113499_bib16","first-page":"197","article-title":"Immunotherapy: bewitched, bothered, and bewildered no more","volume":"305","author":"Steinman","year":"1979","journal-title":"Science"},{"key":"10.1016\/j.biopha.2022.113499_bib17","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.cell.2010.01.022","article-title":"Pattern recognition receptors and inflammation","volume":"140","author":"Takeuchi","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2022.113499_bib18","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/ni.3123","article-title":"Control of adaptive immunity by the innate immune system","volume":"16","author":"Iwasaki","year":"2015","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.biopha.2022.113499_bib19","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrg2703","article-title":"Origin and evolution of the adaptive immune system: genetic events and selective pressures","volume":"11","author":"Flajnik","year":"2010","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.biopha.2022.113499_bib20","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/ni.3123","article-title":"Control of adaptive immunity by the innate immune system","volume":"16","author":"Iwasaki","year":"2015","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.biopha.2022.113499_bib21","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.cell.2015.08.034","article-title":"Deciphering the DNA damage response","volume":"162","author":"Haber","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2022.113499_bib22","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1083\/jcb.143.7.1883","article-title":"Aggresomes: a cellular response to misfolded proteins","volume":"143","author":"Johnston","year":"1998","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.biopha.2022.113499_bib23","doi-asserted-by":"crossref","first-page":"10672","DOI":"10.1523\/JNEUROSCI.23-33-10672.2003","article-title":"Emerging role for autophagy in the removal of aggresomes in Schwann cells","volume":"23","author":"Fortun","year":"2003","journal-title":"J. Neurosci."},{"key":"10.1016\/j.biopha.2022.113499_bib24","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41590-017-0013-y","article-title":"Oxeiptosis, a ROS-induced caspase-independent apoptosis-like cell-death pathway","volume":"19","author":"Holze","year":"2018","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.biopha.2022.113499_bib25","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.plipres.2018.12.002","article-title":"Cholesterol transport system: An integrated cholesterol transport model involved in atherosclerosis","volume":"73","author":"Yu","year":"2019","journal-title":"Prog. Lipid Res."},{"key":"10.1016\/j.biopha.2022.113499_bib26","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/ni.1636","article-title":"The NALP3 inflammasome is involved in the innate immune response to amyloid-\u03b2","volume":"9","author":"Halle","year":"2008","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.biopha.2022.113499_bib27","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/nature08938","article-title":"NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals","volume":"464","author":"Duewell","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2022.113499_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.jiph.2020.07.001","article-title":"Immune response in COVID-19: A review","author":"Chowdhury","year":"2020","journal-title":"J. Infect. Public Health"},{"key":"10.1016\/j.biopha.2022.113499_bib29","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/1741-7007-8-84","article-title":"Assessing the human immune system through blood transcriptomics","volume":"8","author":"Chaussabel","year":"2010","journal-title":"BMC Biol."},{"key":"10.1016\/j.biopha.2022.113499_bib30","first-page":"1","article-title":"Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic","volume":"38","author":"Prompetchara","year":"2020","journal-title":"Asian Pac. J. Allergy Immunol."},{"key":"10.1016\/j.biopha.2022.113499_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2020.108448","article-title":"COVID-19: immunology and treatment options","author":"Felsenstein","year":"2020","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.biopha.2022.113499_bib32","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2022.113499_bib33","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","author":"Zhu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2022.113499_bib34","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nrmicro.2016.81","article-title":"SARS and MERS: Recent insights into emerging coronaviruses","volume":"14","author":"De Wit","year":"2016","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.biopha.2022.113499_bib35","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.antiviral.2016.11.006","article-title":"T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV","volume":"137","author":"Liu","year":"2017","journal-title":"Antivir. Res"},{"key":"10.1016\/j.biopha.2022.113499_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.05.015","article-title":"Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals","author":"Grifoni","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2022.113499_bib37","doi-asserted-by":"crossref","unstructured":"A. Mostaghimi, M.-J. Antonini, D. Plana, P.D. Anderson, B. Beller, E.W. Boyer, A. Fannin, J. Freake, R. Oakley, M.S. Sinha, Rapid prototyping and clinical testing of a reusable face shield for health care workers responding to the COVID-19 pandemic, MedRxiv, 2020.","DOI":"10.1101\/2020.04.11.20061960"},{"key":"10.1016\/j.biopha.2022.113499_bib38","article-title":"Presence of SARS-CoV-2 reactive T cells in COVID-19 patients and healthy donors. medRxiv","volume":"22","author":"Braun","year":"2020","journal-title":"Prepr. Post. Online April"},{"key":"10.1016\/j.biopha.2022.113499_bib39","doi-asserted-by":"crossref","unstructured":"N. Le Bert, A.T. Tan, K. Kunasegaran, C.Y.L. Tham, M. Hafezi, A. Chia, M. Chng, M. Lin, N. Tan, M. Linster, Different pattern of pre-existing SARS-COV-2 specific T cell immunity in SARS-recovered and uninfected individuals, BioRxiv, 2020.","DOI":"10.1101\/2020.05.26.115832"},{"key":"10.1016\/j.biopha.2022.113499_bib40","doi-asserted-by":"crossref","unstructured":"B.J. Meckiff, C. Ram\u00edrez-Su\u00e1stegui, V. Fajardo, S.J. Chee, A. Kusnadi, H. Simon, A. Grifoni, E. Pelosi, D. Weiskopf, A. Sette, Single-cell transcriptomic analysis of SARS-CoV-2 reactive CD4+ T cells, Available at SSRN 3641939, 2020.","DOI":"10.2139\/ssrn.3641939"},{"key":"10.1016\/j.biopha.2022.113499_bib41","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1128\/CVI.00278-10","article-title":"Prevalence of antibodies to four human coronaviruses is lower in nasal secretions than in serum","volume":"17","author":"Gorse","year":"2010","journal-title":"Clin. Vaccin. Immunol."},{"key":"10.1016\/j.biopha.2022.113499_bib42","article-title":"Presence of SARS-CoV-2 reactive T cells in COVID-19 patients and healthy donors. medRxiv","volume":"22","author":"Braun","year":"2020","journal-title":"Prepr. Post. Online April"},{"key":"10.1016\/j.biopha.2022.113499_bib43","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.immuni.2016.05.006","article-title":"Airway memory CD4+ T cells mediate protective immunity against emerging respiratory coronaviruses","volume":"44","author":"Zhao","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.biopha.2022.113499_bib44","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1111\/all.14364","article-title":"Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19","volume":"75","author":"Azkur","year":"2020","journal-title":"Allergy: Eur. J. Allergy Clin. Immunol."},{"key":"10.1016\/j.biopha.2022.113499_bib45","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13429","article-title":"Deciphering the COVID-19 cytokine storm: Systematic review and meta-analysis","volume":"51","author":"Mulchandani","year":"2021","journal-title":"Eur. J. Clin. Investig."},{"key":"10.1016\/j.biopha.2022.113499_bib46","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/j.cell.2021.02.029","article-title":"COVID-19 and the human innate immune system","volume":"184","author":"Schultze","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2022.113499_bib47","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/jid.1984.33","article-title":"The role of antibody and complement in the control of viral infections","volume":"83","author":"Cooper","year":"1984","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.biopha.2022.113499_bib48","doi-asserted-by":"crossref","first-page":"630","DOI":"10.3389\/fimmu.2014.00630","article-title":"Plasticity of human CD4 T cell subsets","volume":"5","author":"Geginat","year":"2014","journal-title":"Front Immunol."},{"key":"10.1016\/j.biopha.2022.113499_bib49","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nri3803","article-title":"A brief history of T cell help to B cells","volume":"15","author":"Crotty","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.biopha.2022.113499_bib50","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005191","article-title":"Induction of ICOS+ CXCR3+ CXCR5+ TH cells correlates with antibody responses to influenza vaccination","volume":"5","author":"Bentebibel","year":"2013","journal-title":"Sci. Transl. Med"},{"key":"10.1016\/j.biopha.2022.113499_bib51","doi-asserted-by":"crossref","first-page":"14330","DOI":"10.1073\/pnas.1311998110","article-title":"Human circulating influenza-CD4+ ICOS1+ IL-21+ T cells expand after vaccination, exert helper function, and predict antibody responses","volume":"110","author":"Spensieri","year":"2013","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.biopha.2022.113499_bib52","doi-asserted-by":"crossref","first-page":"4836","DOI":"10.4049\/jimmunol.1402071","article-title":"MF59 mediates its B cell adjuvanticity by promoting T follicular helper cells and thus germinal center responses in adult and early life","volume":"194","author":"Gavillet","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.biopha.2022.113499_bib53","series-title":"Semin Immunopathol","first-page":"79","article-title":"Th17 cytokines and vaccine-induced immunity","author":"Lin","year":"2010"},{"key":"10.1016\/j.biopha.2022.113499_bib54","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.coi.2013.03.011","article-title":"Th17 cell based vaccines in mucosal immunity","volume":"25","author":"Kumar","year":"2013","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.biopha.2022.113499_bib55","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/nri2785","article-title":"FOXP3+ regulatory T cells in the human immune system","volume":"10","author":"Sakaguchi","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.biopha.2022.113499_bib56","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1586\/14760584.3.1.23","article-title":"Antibody regulation of T-cell immunity: implications for vaccine strategies against intracellular pathogens","volume":"3","author":"Igietseme","year":"2004","journal-title":"Expert Rev. Vaccin."},{"key":"10.1016\/j.biopha.2022.113499_bib57","unstructured":"W.H. Organization, Draft landscape of COVID-19 candidate vaccines\u201423 April 2020, 2020."},{"key":"10.1016\/j.biopha.2022.113499_bib58","article-title":"The natural history and transmission potential of asymptomatic SARS-CoV-2 infection","author":"Chau","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.biopha.2022.113499_bib59","unstructured":"P. Poletti, M. Tirani, D. Cereda, F. Trentini, G. Guzzetta, G. Sabatino, V. Marziano, A. Castrofino, F. Grosso, G. Del Castillo, Probability of symptoms and critical disease after SARS-CoV-2 infection, ArXiv Preprint ArXiv:2006.08471. (2020)."},{"key":"10.1016\/j.biopha.2022.113499_bib60","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/s41591-020-0965-6","article-title":"Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections","volume":"26","author":"Long","year":"2020","journal-title":"Nat. Med"},{"key":"10.1016\/j.biopha.2022.113499_bib61","doi-asserted-by":"crossref","first-page":"9804","DOI":"10.1073\/pnas.0403492101","article-title":"Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity","volume":"101","author":"Buchholz","year":"2004","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.biopha.2022.113499_bib62","doi-asserted-by":"crossref","DOI":"10.3390\/v12030254","article-title":"Preliminary identification of potential vaccine targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies","volume":"12","author":"Ahmed","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.biopha.2022.113499_bib63","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0168-1702(99)00017-9","article-title":"Phylogenetic analysis of a highly conserved region of the polymerase gene from 11 coronaviruses and development of a consensus polymerase chain reaction assay","volume":"60","author":"Stephensen","year":"1999","journal-title":"Virus Res"},{"issue":"2020","key":"10.1016\/j.biopha.2022.113499_bib64","first-page":"779","article-title":"Structure of the RNA-dependent RNA polymerase from COVID-19 virus","volume":"368","author":"Gao","year":"1979","journal-title":"Science"},{"key":"10.1016\/j.biopha.2022.113499_bib65","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.3389\/fimmu.2018.01963","article-title":"New vaccine technologies to combat outbreak situations","volume":"9","author":"Rauch","year":"2018","journal-title":"Front Immunol."},{"key":"10.1016\/j.biopha.2022.113499_bib66","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.it.2018.01.006","article-title":"New tuberculosis vaccine strategies: taking aim at un-natural immunity","volume":"39","author":"Jeyanathan","year":"2018","journal-title":"Trends Immunol."},{"key":"10.1016\/j.biopha.2022.113499_bib67","doi-asserted-by":"crossref","first-page":"16030","DOI":"10.1038\/mtm.2016.30","article-title":"Methods and clinical development of adenovirus-vectored vaccines against mucosal pathogens","volume":"3","author":"Afkhami","year":"2016","journal-title":"Mol. Ther. -Methods Clin. Dev."},{"key":"10.1016\/j.biopha.2022.113499_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2020.07.005","article-title":"Lessons for COVID-19 immunity from other coronavirus infections","author":"Sariol","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.biopha.2022.113499_bib69","doi-asserted-by":"crossref","unstructured":"L. Moreno-Fierros, I. Garc\u00eda-Silva, S. Rosales-Mendoza, Development of SARS-CoV-2 vaccines: should we focus on mucosal immunity?, 2020.","DOI":"10.1080\/14712598.2020.1767062"},{"key":"10.1016\/j.biopha.2022.113499_bib70","doi-asserted-by":"crossref","first-page":"6883","DOI":"10.4049\/jimmunol.0901466","article-title":"What role does the route of immunization play in the generation of protective immunity against mucosal pathogens?","volume":"183","author":"Belyakov","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.biopha.2022.113499_bib71","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.it.2018.01.006","article-title":"New tuberculosis vaccine strategies: taking aim at un-natural immunity","volume":"39","author":"Jeyanathan","year":"2018","journal-title":"Trends Immunol."},{"key":"10.1016\/j.biopha.2022.113499_bib72","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/j.cell.2018.09.042","article-title":"Induction of autonomous memory alveolar macrophages requires T cell help and is critical to trained immunity","volume":"175","author":"Yao","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2022.113499_bib73","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.immuni.2016.05.006","article-title":"Airway memory CD4+ T cells mediate protective immunity against emerging respiratory coronaviruses","volume":"44","author":"Zhao","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.biopha.2022.113499_bib74","doi-asserted-by":"crossref","first-page":"16030","DOI":"10.1038\/mtm.2016.30","article-title":"Methods and clinical development of adenovirus-vectored vaccines against mucosal pathogens","volume":"3","author":"Afkhami","year":"2016","journal-title":"Mol. Ther. -Methods Clin. Dev."},{"key":"10.1016\/j.biopha.2022.113499_bib75","doi-asserted-by":"crossref","first-page":"M563","DOI":"10.1093\/gerona\/57.9.M563","article-title":"Effect of a complete nutritional supplement on antibody response to influenza vaccine in elderly people","volume":"57","author":"Wouters-Wesseling","year":"2002","journal-title":"J. Gerontol. Ser. A: Biol. Sci. Med. Sci."},{"key":"10.1016\/j.biopha.2022.113499_bib76","first-page":"218","article-title":"Association of nutraceutical supplements with longer telomere length","volume":"44","author":"Tsoukalas","year":"2019","journal-title":"Int J. Mol. Med"},{"key":"10.1016\/j.biopha.2022.113499_bib77","first-page":"21","article-title":"Immunosenescence in aging: between immune cells depletion and cytokines up-regulation, Clinical and Molecular","volume":"15","author":"Ventura","year":"2017","journal-title":"Allergy"},{"key":"10.1016\/j.biopha.2022.113499_bib78","doi-asserted-by":"crossref","first-page":"2154S","DOI":"10.3945\/jn.109.105312","article-title":"Landscape analysis of interactions between nutrition and vaccine responses in children","volume":"139","author":"Savy","year":"2009","journal-title":"J. Nutr."},{"key":"10.1016\/j.biopha.2022.113499_bib79","doi-asserted-by":"crossref","first-page":"181","DOI":"10.5152\/tpa.2014.2206","article-title":"Vaccination in patients with immunosuppression","volume":"49","author":"Arvas","year":"2014","journal-title":"Turk. Arch. Pediatr. \/T\u00fcrk Pediatr. Ar\u015fivi"},{"key":"10.1016\/j.biopha.2022.113499_bib80","article-title":"(2012): Report of the Committee on Infectious Diseases","author":"Pickering","year":"2012","journal-title":"Am. Acad. Pediatr."},{"key":"10.1016\/j.biopha.2022.113499_bib81","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/08916930600597326","article-title":"Reduced tetanus antibody titers in overweight children","volume":"39","author":"Eliakim","year":"2006","journal-title":"Autoimmunity"},{"key":"10.1016\/j.biopha.2022.113499_bib82","first-page":"946","article-title":"Etiological diagnosis and pharmacotherapeutic management of parapneumonic pleurisy","volume":"64","author":"C\u0103lina","year":"2016","journal-title":"Farmacia"},{"key":"10.1016\/j.biopha.2022.113499_bib83","first-page":"17","article-title":"Zinc and respiratory tract infections: Perspectives for COVID-19","volume":"46","author":"Skalny","year":"2020","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.biopha.2022.113499_bib84","series-title":"Understanding Modern Vaccines: Perspectives in Vaccinology","author":"Gar\u00e7on","year":"2011"},{"key":"10.1016\/j.biopha.2022.113499_bib85","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1093\/cid\/ciz135","article-title":"Principal controversies in vaccine safety in the United States","volume":"69","author":"DeStefano","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.biopha.2022.113499_bib86","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0057755","article-title":"Risk in vaccine research and development quantified","volume":"8","author":"Pronker","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2022.113499_bib87","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1038\/nbt0910-910","article-title":"First-in-human clinical trials with vaccines\u2014what regulators want","volume":"28","author":"Goetz","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.biopha.2022.113499_bib88","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1080\/21645515.2019.1586040","article-title":"Safety profile of the RTS, S\/AS01 malaria vaccine in infants and children: additional data from a phase III randomized controlled trial in sub-Saharan Africa","volume":"15","author":"Guerra Mendoza","year":"2019","journal-title":"Hum. Vaccin Immunother."},{"key":"10.1016\/j.biopha.2022.113499_bib89","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2022.113499_bib90","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2022.113499_bib91","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2022.113499_bib92","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2022.113499_bib93","series-title":"FDA Approves First COVID-19 Vaccine","author":"FDA","year":"2021"},{"key":"10.1016\/j.biopha.2022.113499_bib94","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2022.113499_bib95","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2022.113499_bib96","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20202756","article-title":"Immunogenicity and efficacy of one and two doses of Ad26. COV2. S COVID vaccine in adult and aged NHP","volume":"218","author":"Solforosi","year":"2021","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.biopha.2022.113499_bib97","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20202756","article-title":"Immunogenicity and efficacy of one and two doses of Ad26. COV2. S COVID vaccine in adult and aged NHP","volume":"218","author":"Solforosi","year":"2021","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.biopha.2022.113499_bib98","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2022.113499_bib99","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.2147\/IDR.S315727","article-title":"Overview of the Main Anti-SARS-CoV-2 Vaccines: Mechanism of Action, Efficacy and Safety","volume":"14","author":"Mascellino","year":"2021","journal-title":"Infect. Drug Resist"},{"key":"10.1016\/j.biopha.2022.113499_bib100","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.15585\/mmwr.mm695152e1","article-title":"The Advisory Committee on Immunization Practices\u2019 Interim Recommendation for Use of Moderna COVID-19 Vaccine - United States, December 2020","volume":"69","author":"Oliver","year":"2021","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.biopha.2022.113499_bib101","article-title":"Untimely Myocardial Infarction or COVID-19 Vaccine Side Effect","volume":"13","author":"Boivin","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.biopha.2022.113499_bib102","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S0140-6736(20)32623-4","article-title":"Oxford-AstraZeneca COVID-19 vaccine efficacy","volume":"397","author":"Knoll","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2022.113499_bib103","doi-asserted-by":"crossref","first-page":"329","DOI":"10.15585\/mmwr.mm7009e4","article-title":"The Advisory Committee on Immunization Practices\u2019 Interim Recommendation for Use of Janssen COVID-19 Vaccine - United States, February 2021","volume":"70","author":"Oliver","year":"2021","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"10.1016\/j.biopha.2022.113499_bib104","doi-asserted-by":"crossref","first-page":"21464","DOI":"10.1038\/s41598-021-00963-7","article-title":"Side effects and Immunogenicity following administration of the Sputnik V COVID-19 vaccine in health care workers in Iran","volume":"11","author":"Babamahmoodi","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2022.113499_bib105","doi-asserted-by":"crossref","DOI":"10.1016\/j.amsu.2021.102622","article-title":"Shoulder injury related to Sinovac COVID-19 vaccine: A case report","volume":"68","author":"Chuaychoosakoon","year":"2021","journal-title":"Ann. Med. Surg."},{"key":"10.1016\/j.biopha.2022.113499_bib106","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1016\/S0140-6736(21)02000-6","article-title":"Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial","volume":"398","author":"Ella","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2022.113499_bib107","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/S1473-3099(21)00070-0","article-title":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial","volume":"21","author":"Ella","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.biopha.2022.113499_bib108","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.102298","article-title":"Th1 skewed immune response of whole virion inactivated SARS CoV 2 vaccine and its safety evaluation","volume":"24","author":"Ganneru","year":"2021","journal-title":"IScience"},{"key":"10.1016\/j.biopha.2022.113499_bib109","first-page":"1277","article-title":"(An International Multidisciplinary Peer Review Open Access monthly Journal) COVID-19 Vaccines approved for use and under W development in India: An overview","volume":"4","author":"Pawar","year":"2021","journal-title":"J. Pharm. Adv. Res."},{"key":"10.1016\/j.biopha.2022.113499_bib110","first-page":"1","article-title":"Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico","author":"Dunkle","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2022.113499_bib111","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejim.2020.04.037","article-title":"The pivotal link between ACE2 deficiency and SARS-CoV-2 infection","volume":"76","author":"Verdecchia","year":"2020","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.biopha.2022.113499_bib112","doi-asserted-by":"crossref","unstructured":"P.J. Hotez, M.E. Bottazzi, Developing a low-cost and accessible COVID-19 vaccine for global health, 2020.","DOI":"10.1371\/journal.pntd.0008548"},{"key":"10.1016\/j.biopha.2022.113499_bib113","doi-asserted-by":"crossref","unstructured":"T.T. Le, Z. Andreadakis, A. Kumar, R.G. Rom\u00e1n, S. Tollefsen, & M.S., S. Mayhew, The COVID-19 vaccine development landscape, 2020.","DOI":"10.1038\/d41573-020-00073-5"},{"key":"10.1016\/j.biopha.2022.113499_bib114","doi-asserted-by":"crossref","unstructured":"P.J. Hotez, M.E. Bottazzi, Developing a low-cost and accessible COVID-19 vaccine for global health, 2020.","DOI":"10.1371\/journal.pntd.0008548"},{"key":"10.1016\/j.biopha.2022.113499_bib115","first-page":"1","article-title":"COVID-19 Treatment: Investigational Drugs and Other Therapies","author":"Bergman","year":"2021","journal-title":"Medscape"},{"key":"10.1016\/j.biopha.2022.113499_bib116","doi-asserted-by":"crossref","first-page":"7","DOI":"10.21608\/mb.2020.33405.1018","article-title":"COVID-19 coronavirus: pathogenesis, clinical features, diagnostics, epidemiology, prevention and control","volume":"5","author":"El-Fakharany","year":"2020","journal-title":"Microb. Biosyst."},{"key":"10.1016\/j.biopha.2022.113499_bib117","series-title":"Coronavirus Disease 2019 (COVID-19) Treatment Guidelines","author":"COVID-19 Treatment Guidelines Panel","year":"2022"},{"key":"10.1016\/j.biopha.2022.113499_bib118","doi-asserted-by":"crossref","first-page":"93","DOI":"10.7326\/M20-6448","article-title":"Convalescent Plasma for the Treatment of COVID-19: Perspectives of the National Institutes of Health COVID-19 Treatment Guidelines Panel","volume":"174","author":"Pau","year":"2021","journal-title":"Ann. Intern Med"},{"key":"10.1016\/j.biopha.2022.113499_bib119","first-page":"2020","volume":"2020","author":"CDC","year":"2019"},{"key":"10.1016\/j.biopha.2022.113499_bib120","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/jcph.1822","article-title":"Potential COVID-19 Therapeutic Agents and Vaccines: An Evidence-Based Review","volume":"61","author":"Khani","year":"2021","journal-title":"J. Clin. Pharm."},{"key":"10.1016\/j.biopha.2022.113499_bib121","article-title":"Therapeutic strategies to fight COVID-19: Which is the status artis?","author":"Scavone","year":"2021","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.biopha.2022.113499_bib122","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/d41586-021-03074-5","article-title":"COVID antiviral pills: what scientists still want to know","volume":"599","author":"Ledford","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2022.113499_bib123","doi-asserted-by":"crossref","first-page":"n2713","DOI":"10.1136\/bmj.n2713","article-title":"Covid-19: Pfizer\u2019s paxlovid is 89% effective in patients at risk of serious illness, company reports","volume":"375","author":"Mahase","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.biopha.2022.113499_bib124","first-page":"113","article-title":"COVID-19 Treatment Guidelines. Food and Drug Administration, Nonhospitalized Adults: Therapeutic Management","author":"National Institutes of Health","year":"2022","journal-title":"COVID-19 Treat. Guidel."},{"key":"10.1016\/j.biopha.2022.113499_bib125","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the Treatment of Covid-19 \u2014 Final Report","volume":"383","author":"Beigel","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2022.113499_bib126","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.biopha.2022.113499_bib127","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26195795","article-title":"Discovery, development, and patent trends on molnupiravir: A prospective oral treatment for covid-19","volume":"26","author":"Imran","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.biopha.2022.113499_bib128","article-title":"Covid-19: UK becomes first country to authorise antiviral molnupiravir","volume":"375","author":"Mahase","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.biopha.2022.113499_bib129","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.bbrc.2005.05.089","article-title":"A human SARS-CoV neutralizing antibody against epitope on S2 protein","volume":"333","author":"Duan","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.biopha.2022.113499_bib130","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa2035002","article-title":"REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19","volume":"384","author":"Weinreich","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2022.113499_bib131","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1001\/jama.2022.2832","article-title":"Effect of Sotrovimab on Hospitalization or Death among High-risk Patients with Mild to Moderate COVID-19: A Randomized Clinical Trial","volume":"327","author":"Gupta","year":"2022","journal-title":"JAMA - J. Am. Med. Assoc."},{"key":"10.1016\/j.biopha.2022.113499_bib132","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/s41586-021-04386-2","article-title":"Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift","volume":"602","author":"Cameroni","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2022.113499_bib133","doi-asserted-by":"crossref","first-page":"o1009","DOI":"10.1136\/bmj.o1009","article-title":"Covid-19: Has the spread of omicron BA.2 made antibody treatments redundant?","volume":"377","author":"Mahase","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.biopha.2022.113499_bib134","doi-asserted-by":"crossref","first-page":"599","DOI":"10.3390\/covid2050045","article-title":"Monoclonal Antibodies as Potential COVID-19 Therapeutic Agents","volume":"2","author":"Plichta","year":"2022","journal-title":"COVID"},{"key":"10.1016\/j.biopha.2022.113499_bib135","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1001\/jama.2020.13170","article-title":"COVID-19 and Dexamethasone: A Potential Strategy to Avoid Steroid-Related Strongyloides Hyperinfection","volume":"324","author":"Stauffer","year":"2020","journal-title":"JAMA - J. Am. Med. Assoc."},{"key":"10.1016\/j.biopha.2022.113499_bib136","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa2028700","article-title":"Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia","volume":"384","author":"Rosas","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2022.113499_bib137","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1001\/jamainternmed.2020.6252","article-title":"Association between Early Treatment with Tocilizumab and Mortality among Critically Ill Patients with COVID-19","volume":"181","author":"Gupta","year":"2021","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.biopha.2022.113499_bib138","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/jmv.27285","article-title":"Evolution of viral variants in remdesivir-treated and untreated SARS-CoV-2-infected pediatrics patients","volume":"94","author":"Boshier","year":"2022","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.biopha.2022.113499_bib139","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12985-021-01700-2","article-title":"Evaluation of the therapeutic regimen in COVID-19 in transplant patients: where do immunomodulatory and antivirals stand?","volume":"18","author":"Shafiekhani","year":"2021","journal-title":"Virol. J."},{"key":"10.1016\/j.biopha.2022.113499_bib140","unstructured":"A. Adarsh Bhimraj, R.L. Morgan, A. Hirsch Shumaker, V. Lavergne, L. Baden, V. Chi-Chung Cheng, K.M. Edwards, R. Gandhi, J. Gallagher, W.J. Muller, J.C. O, S. Shoham, M. Hassan Murad, R.A. Mustafa, S. Sultan, Y. Falck-Ytter, Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19, n.d. www.idsociety.org\/COVID19guidelines."},{"key":"10.1016\/j.biopha.2022.113499_bib141","unstructured":"FDA, Coronavirus (COVID-19) Update: FDA Authorizes First Oral Antiviral for Treatment of COVID-19, 2021."},{"key":"10.1016\/j.biopha.2022.113499_bib142","doi-asserted-by":"crossref","first-page":"n2602","DOI":"10.1136\/bmj.n2602","article-title":"Covid-19: UK stockpiles two unapproved antiviral drugs for treatment at home","volume":"375","author":"Mahase","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.biopha.2022.113499_bib143","unstructured":"FDA, Coronavirus (COVID-19) Update: FDA Authorizes Additional Oral Antiviral for Treatment of COVID-19 in Certain Adults, (2021)."},{"key":"10.1016\/j.biopha.2022.113499_bib144","doi-asserted-by":"crossref","first-page":"n2602","DOI":"10.1136\/bmj.n2602","article-title":"Covid-19: UK stockpiles two unapproved antiviral drugs for treatment at home","volume":"375","author":"Mahase","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.biopha.2022.113499_bib145","first-page":"1","article-title":"Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients","author":"Jayk Bernal","year":"2021","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.biopha.2022.113499_bib146","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41594-021-00651-0","article-title":"Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis","volume":"28","author":"Kabinger","year":"2021","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.biopha.2022.113499_bib147","article-title":"file:\/\/\/C:\/Users\/USER\/Downloads\/32251767.nbib","volume":"55","author":"Devaux","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.biopha.2022.113499_bib148","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104786","article-title":"Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro","volume":"178","author":"Choy","year":"2020","journal-title":"Antivir. Res"},{"key":"10.1016\/j.biopha.2022.113499_bib149","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41421-018-0034-1","article-title":"Emetine inhibits Zika and Ebola virus infections through two molecular mechanisms: Inhibiting viral replication and decreasing viral entry","volume":"4","author":"Yang","year":"2018","journal-title":"Cell Discov."},{"key":"10.1016\/j.biopha.2022.113499_bib150","article-title":"Emetine, Ipecac, Ipecac Alkaloids and Analogues as Potential Antiviral Agents for Coronaviruses","volume":"13","author":"Bleasel","year":"2020","journal-title":"Pharm. (Basel)"},{"key":"10.1016\/j.biopha.2022.113499_bib151","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104787","article-title":"The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro","volume":"178","author":"Caly","year":"2020","journal-title":"Antivir. Res"},{"key":"10.1016\/j.biopha.2022.113499_bib152","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1080\/07391102.2020.1772885","article-title":"Repurposing approved drugs as inhibitors of SARS-CoV-2\u2009S-protein from molecular modeling and virtual screening","volume":"39","author":"de Oliveira","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.biopha.2022.113499_bib153","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.21873\/invivo.12134","article-title":"Ivermectin Docks to the SARS-CoV-2 Spike Receptor-binding Domain Attached to ACE2","volume":"34","author":"Lehrer","year":"2020","journal-title":"Vivo"},{"key":"10.1016\/j.biopha.2022.113499_bib154","article-title":"Ivermectin for preventing and treating COVID-19","volume":"7","author":"Popp","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.biopha.2022.113499_bib155","article-title":"Chloroquine or hydroxychloroquine for prevention and treatment of COVID\u201019","author":"Singh","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.biopha.2022.113499_bib156","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2020.01708","article-title":"Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies","volume":"11","author":"Tang","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2022.113499_bib157","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.2147\/JIR.S322831","article-title":"Immunomodulation as a potent COVID-19 pharmacotherapy: Past, present and future","volume":"14","author":"Hertanto","year":"2021","journal-title":"J. Inflamm. Res."},{"key":"10.1016\/j.biopha.2022.113499_bib158","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/acn3.84","article-title":"Immunomodulatory activity of interferon-beta","volume":"1","author":"Kasper","year":"2014","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.biopha.2022.113499_bib159","first-page":"204","article-title":"Recent advances on the immunomodulatory effects of IFN-alpha: implications for cancer immunotherapy and autoimmunity., Autoimmunity","volume":"43","author":"Rizza","year":"2010"},{"key":"10.1016\/j.biopha.2022.113499_bib160","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103642","article-title":"Off balance: Interferons in COVID-19 lung infections","volume":"73","author":"Akamatsu","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.biopha.2022.113499_bib161","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1093\/cid\/ciz544","article-title":"Ribavirin and Interferon Therapy for Critically Ill Patients With Middle East Respiratory Syndrome: A Multicenter Observational Study","volume":"70","author":"Arabi","year":"2020","journal-title":"Clin. Infect. Dis.: Off. Publ. Infect. Dis. Soc. Am."},{"key":"10.1016\/j.biopha.2022.113499_bib162","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-021-86859-y","article-title":"Role of interferon therapy in severe COVID-19: the COVIFERON randomized controlled trial","volume":"11","author":"Alavi Darazam","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2022.113499_bib163","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/ijcp.14721","article-title":"Do interferons play a role in COVID-19?","volume":"75","author":"Arasteh","year":"2021","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.biopha.2022.113499_bib164","first-page":"1365","article-title":"Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial., Lancet","volume":"9","author":"Kalil","year":"2021","journal-title":"Respir. Med"},{"key":"10.1016\/j.biopha.2022.113499_bib165","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2022.113499_bib166","unstructured":"Y.M. Arabi, F. Ya, Corticosteroid Therapy for Critically ill Patients with the Middle East Respiratory Syndrome, 2017: 1\u201346."},{"key":"10.1016\/j.biopha.2022.113499_bib167","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/BF00542111","article-title":"Relative immunosuppressive potency of various corticosteroids measured in vitro","volume":"25","author":"Langhoff","year":"1983","journal-title":"Eur. J. Clin. Pharm."},{"key":"10.1016\/j.biopha.2022.113499_bib168","doi-asserted-by":"crossref","first-page":"e373","DOI":"10.1093\/cid\/ciaa1177","article-title":"file:\/\/\/C:\/Users\/USER\/Downloads\/19028526.nbib","volume":"72","author":"Jeronimo","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.biopha.2022.113499_bib169","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.antiviral.2008.10.009","article-title":"Characteristics of arbidol-resistant mutants of influenza virus: Implications for the mechanism of anti-influenza action of arbidol","volume":"81","author":"Leneva","year":"2009","journal-title":"Antivir. Res."},{"key":"10.1016\/j.biopha.2022.113499_bib170","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jaci.2020.05.021","article-title":"Successful use of methylprednisolone for treating severe COVID-19","volume":"146","author":"Liu","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.biopha.2022.113499_bib171","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in Hospitalized Patients with Covid-19","volume":"384","author":"Group","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2022.113499_bib172","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s40121-020-00332-3","article-title":"Efficacy Evaluation of Early, Low-Dose, Short-Term Corticosteroids in Adults Hospitalized with Non-Severe COVID-19 Pneumonia: A Retrospective Cohort Study","volume":"9","author":"Li","year":"2020","journal-title":"Infect. Dis. Ther."},{"key":"10.1016\/j.biopha.2022.113499_bib173","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.12688\/f1000research.73606.1","article-title":"Clinical use of antiviral, antibiotic and immunomodulatory drugs in hospitalized COVID-19 patients: a retrospective study in Bandung, Indonesia","volume":"10","author":"Muflihah","year":"2021","journal-title":"F1000Res"},{"key":"10.1016\/j.biopha.2022.113499_bib174","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-78039-1","article-title":"Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19","volume":"10","author":"Spagnuolo","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2022.113499_bib175","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1002\/jmv.25948","article-title":"Elevated interleukin-6 and severe COVID-19: A meta-analysis","volume":"92","author":"Aziz","year":"2020","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.biopha.2022.113499_bib176","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13054-020-03062-7","article-title":"The vascular endothelium: The cornerstone of organ dysfunction in severe SARS-CoV-2 infection","volume":"24","author":"Pons","year":"2020","journal-title":"Crit. Care"},{"key":"10.1016\/j.biopha.2022.113499_bib177","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102568","article-title":"Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy","volume":"19","author":"Toniati","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.biopha.2022.113499_bib178","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa2028700","article-title":"Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia","volume":"384","author":"Rosas","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2022.113499_bib179","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0168-1702(99)00121-5","article-title":"Characterization of antiviral activity of lactoferrin against hepatitis C virus infection in human cultured cells","volume":"66","author":"Ikeda","year":"2000","journal-title":"Virus Res."},{"key":"10.1016\/j.biopha.2022.113499_bib180","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.ijbiomac.2020.09.235","article-title":"Nanoformulation of lactoferrin potentiates its activity and enhances novel biotechnological applications","volume":"165","author":"El-Fakharany","year":"2020","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.biopha.2022.113499_bib181","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.crvi.2014.08.003","article-title":"Potential lactoferrin activity against pathogenic viruses","volume":"337","author":"Redwan","year":"2014","journal-title":"Comptes Rendus - Biol."},{"key":"10.1016\/j.biopha.2022.113499_bib182","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms21144903","article-title":"Lactoferrin as protective natural barrier of respiratory and intestinal mucosa against coronavirus infection and inflammation","volume":"21","author":"Campione","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2022.113499_bib183","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.jiac.2014.08.003","article-title":"Lactoferrin for prevention of common viral infections","volume":"20","author":"Wakabayashi","year":"2014","journal-title":"J. Infect. Chemother."},{"key":"10.1016\/j.biopha.2022.113499_bib184","doi-asserted-by":"crossref","DOI":"10.3892\/etm.2017.4159","article-title":"Influence of camel milk on the hepatitis C virus burden of infected patients","volume":"13","author":"El-Fakharany","year":"2017","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.biopha.2022.113499_bib185","article-title":"In vitro exploration of the anti-hcv potential of the synthetic spacer peptides derived from human, bovine, and camel lactoferrins","volume":"24","author":"Albar","year":"2017","journal-title":"Protein Pept. Lett."},{"key":"10.1016\/j.biopha.2022.113499_bib186","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.cell.2020.09.033","article-title":"SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2","volume":"183","author":"Clausen","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2022.113499_bib187","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/aps.2013.200","article-title":"Immunomodulatory effects of lactoferrin","volume":"35","author":"Siqueiros-Cend\u00f3n","year":"2014","journal-title":"Acta Pharm. Sin."},{"key":"10.1016\/j.biopha.2022.113499_bib188","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s10534-014-9740-9","article-title":"Lactoferrin differently modulates the inflammatory response in epithelial models mimicking human inflammatory and infectious diseases","volume":"27","author":"Frioni","year":"2014","journal-title":"BioMetals"},{"key":"10.1016\/j.biopha.2022.113499_bib189","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/nu13020328","article-title":"Protective effects of lactoferrin against sars-cov-2 infection in vitro","volume":"13","author":"Salaris","year":"2021","journal-title":"Nutrients"},{"key":"10.1016\/j.biopha.2022.113499_bib190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2021.666600","article-title":"Lactoferrin Against SARS-CoV-2: In Vitro and In Silico Evidences","volume":"12","author":"Campione","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2022.113499_bib191","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijerph182010985","article-title":"Lactoferrin as antiviral treatment in COVID-19 management: Preliminary evidence","volume":"18","author":"Campione","year":"2021","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"10.1016\/j.biopha.2022.113499_bib192","doi-asserted-by":"crossref","DOI":"10.1177\/1076029620938149","article-title":"COVID-19: Coagulopathy, Risk of Thrombosis, and the Rationale for Anticoagulation","volume":"26","author":"Miesbach","year":"2020","journal-title":"Clin. Appl. Thromb. \/Hemost."},{"key":"10.1016\/j.biopha.2022.113499_bib193","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1111\/jth.14820","article-title":"Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia","volume":"18","author":"Arachchillage","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.biopha.2022.113499_bib194","article-title":"Thromboelastography to Detect Hypercoagulability and Reduced Fibrinolysis in Coronavirus Disease 2019 Acute Respiratory Distress Syndrome Patients","volume":"2","author":"Sadd","year":"2020","journal-title":"Crit. Care Explor"},{"key":"10.1016\/j.biopha.2022.113499_bib195","first-page":"1","article-title":"Anticoagulation in COVID-19: Current concepts and controversies","author":"Chandra","year":"2021","journal-title":"Postgrad. Med. J."},{"key":"10.1016\/j.biopha.2022.113499_bib196","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2022.113499_bib197","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ijcard.2020.09.064","article-title":"Antithrombotic therapy in patients with COVID-19? -Rationale and Evidence","volume":"324","author":"Godino","year":"2021","journal-title":"Int J. Cardiol."},{"key":"10.1016\/j.biopha.2022.113499_bib198","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2020.573044","article-title":"Heparin Therapy Improving Hypoxia in COVID-19 Patients - A Case Series","volume":"11","author":"Negri","year":"2020","journal-title":"Front Physiol."},{"key":"10.1016\/j.biopha.2022.113499_bib199","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1111\/cts.12880","article-title":"The Potential of Low Molecular Weight Heparin to Mitigate Cytokine Storm in Severe COVID-19 Patients: A Retrospective Cohort Study","volume":"13","author":"Shi","year":"2020","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.biopha.2022.113499_bib200","article-title":"Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: Cohort study","volume":"372","author":"Rentsch","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.biopha.2022.113499_bib201","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1136\/heartjnl-2021-319552","article-title":"Antiplatelet therapy and outcome in COVID-19: the Health Outcome Predictive Evaluation Registry","volume":"108","author":"Santoro","year":"2022","journal-title":"Heart"},{"key":"10.1016\/j.biopha.2022.113499_bib202","article-title":"Potential Role of Vitamins and Zinc on Acute Respiratory Infections Including Covid-19","volume":"8","author":"Murni","year":"2021","journal-title":"Glob. Pediatr. Health"},{"key":"10.1016\/j.biopha.2022.113499_bib203","author":"Gammoh","year":"2017","journal-title":"Zinc Infect. Inflamm."},{"key":"10.1016\/j.biopha.2022.113499_bib204","first-page":"696","author":"Read","year":"2019","journal-title":"Role Zinc Antivir. Immun."},{"key":"10.1016\/j.biopha.2022.113499_bib205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/nu12103198","article-title":"The role of micronutrients in support of the immune response against viral infections","volume":"12","author":"Pecora","year":"2020","journal-title":"Nutrients"},{"key":"10.1016\/j.biopha.2022.113499_bib206","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.jiac.2014.08.003","article-title":"Lactoferrin for prevention of common viral infections","volume":"20","author":"Wakabayashi","year":"2014","journal-title":"J. Infect. Chemother."},{"key":"10.1016\/j.biopha.2022.113499_bib207","volume":"7","author":"Lubberts","year":"2017","journal-title":"Vitam. D. Autoimmun.: Mol. Mech. Ther. Potential"},{"key":"10.1016\/j.biopha.2022.113499_bib208","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/nu12103198","article-title":"The role of micronutrients in support of the immune response against viral infections","volume":"12","author":"Pecora","year":"2020","journal-title":"Nutrients"},{"key":"10.1016\/j.biopha.2022.113499_bib209","doi-asserted-by":"crossref","unstructured":"G. Costagliola, E. Spada, P. Comberiati, D.G. Peroni, Could nutritional supplements act as therapeutic adjuvants in COVID-19\u00a0?, 0 (2021) 1\u20135.","DOI":"10.1186\/s13052-021-00990-0"},{"key":"10.1016\/j.biopha.2022.113499_bib210","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s40618-020-01370-x","article-title":"Vitamin D deficiency as a predictor of poor prognosis in patients with acute respiratory failure due to COVID - 19","volume":"44","author":"Di","year":"2021","journal-title":"J. Endocrinol. Investig."},{"key":"10.1016\/j.biopha.2022.113499_bib211","doi-asserted-by":"crossref","unstructured":"G. Costagliola, E. Spada, P. Comberiati, D.G. Peroni, Could nutritional supplements act as therapeutic adjuvants in COVID-19\u00a0?, 0 (2021) 1\u20135.","DOI":"10.1186\/s13052-021-00990-0"},{"key":"10.1016\/j.biopha.2022.113499_bib212","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pmed.1003605","article-title":"Vitamin D and COVID-19 susceptibility and severity in the COVID-19 host genetics initiative: A Mendelian randomization study","volume":"18","author":"Butler-Laporte","year":"2021","journal-title":"PLoS Med."},{"key":"10.1016\/j.biopha.2022.113499_bib213","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ofid\/ofab408","article-title":"Vitamin K & D Deficiencies are independently associated with COVID-19 disease severity","volume":"8","author":"Desai","year":"2021","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.biopha.2022.113499_bib214","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamanetworkopen.2021.0369","article-title":"Effect of High-Dose Zinc and Ascorbic Acid Supplementation vs Usual Care on Symptom Length and Reduction among Ambulatory Patients with SARS-CoV-2 Infection: The COVID A to Z Randomized Clinical Trial","volume":"4","author":"Thomas","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.biopha.2022.113499_bib215","article-title":"Potential Role of Vitamins and Zinc on Acute Respiratory Infections Including Covid-19","volume":"8","author":"Murni","year":"2021","journal-title":"Glob. Pediatr. Health"},{"key":"10.1016\/j.biopha.2022.113499_bib216","doi-asserted-by":"crossref","first-page":"93","DOI":"10.7326\/M20-6448","article-title":"Convalescent Plasma for the Treatment of COVID-19: Perspectives of the National Institutes of Health COVID-19 Treatment Guidelines Panel","volume":"174","author":"Pau","year":"2021","journal-title":"Ann. Intern Med"},{"key":"10.1016\/j.biopha.2022.113499_bib217","doi-asserted-by":"crossref","first-page":"E745","DOI":"10.1503\/cmaj.200642","article-title":"Efficacy and safety of convalescent plasma for severe COVID-19 based on evidence in other severe respiratory viral infections: a systematic review and meta-analysis","volume":"192","author":"Devasenapathy","year":"2020","journal-title":"Cmaj"},{"key":"10.1016\/j.biopha.2022.113499_bib218","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJM200307313490520","article-title":"Profile of specific antibodies to the SARS-associated coronavirus","volume":"349","author":"Li","year":"2003","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.biopha.2022.113499_bib219","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-021-06451-7","article-title":"Usefulness of convalescent plasma transfusion for the treatment of severely ill COVID-19 patients in Pakistan","volume":"21","author":"Khan","year":"2021","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.biopha.2022.113499_bib220","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1055\/s-0040-1716594","article-title":"Convalescent Plasma Therapy for COVID-19: Current Status and Future Directions","volume":"7","author":"Seshan","year":"2020","journal-title":"J. Neuroanaesth. Crit. Care"},{"key":"10.1016\/j.biopha.2022.113499_bib221","doi-asserted-by":"crossref","first-page":"9490","DOI":"10.1073\/pnas.2004168117","article-title":"Effectiveness of convalescent plasma therapy in severe COVID-19 patients","volume":"117","author":"Duan","year":"2020","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.biopha.2022.113499_bib222","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1038\/s41591-021-01488-2","article-title":"Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial","volume":"27","author":"B\u00e9gin","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.biopha.2022.113499_bib223","first-page":"1","article-title":"Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials","volume":"21","author":"Axfors","year":"2021"},{"key":"10.1016\/j.biopha.2022.113499_bib224","unstructured":"W.H. Organization, Therapeutics and COVID-19, 2021."},{"key":"10.1016\/j.biopha.2022.113499_bib225","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcv.2020.104358","article-title":"Challenges of Convalescent Plasma Therapy on COVID-19","volume":"127","author":"Zhao","year":"2020","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.biopha.2022.113499_bib226","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.102898","article-title":"Effect of time and titer in convalescent plasma therapy for COVID-19","volume":"24","author":"de Candia","year":"2021","journal-title":"IScience"},{"key":"10.1016\/j.biopha.2022.113499_bib227","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1001\/jamaoncol.2021.1799","article-title":"Association of Convalescent Plasma Therapy with Survival in Patients with Hematologic Cancers and COVID-19","volume":"7","author":"Thompson","year":"2021","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.biopha.2022.113499_bib228","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1001\/jama.2020.10245","article-title":"Monoclonal antibodies for prevention and treatment of COVID-19","volume":"324","author":"Marovich","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.biopha.2022.113499_bib229","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.cmi.2020.03.026","article-title":"COVID-19, SARS and MERS: are they closely related?","volume":"26","author":"Petrosillo","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.biopha.2022.113499_bib230","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106560","article-title":"Towards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: Anti-antibodies, immunoglobulins, and corticosteroids","volume":"84","author":"Saghazadeh","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.biopha.2022.113499_bib231","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-021-00784-w","article-title":"Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection","volume":"29","author":"Hwang","year":"2022","journal-title":"J. Biomed. Sci."},{"issue":"2020","key":"10.1016\/j.biopha.2022.113499_bib232","first-page":"1014","article-title":"Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies","volume":"369","author":"Baum","year":"1979","journal-title":"Science"},{"key":"10.1016\/j.biopha.2022.113499_bib233","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa2035002","article-title":"REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19","volume":"384","author":"Weinreich","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2022.113499_bib234","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101102","article-title":"Casirivimab\u2013Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19","volume":"40","author":"Razonable","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.biopha.2022.113499_bib235","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa2028700","article-title":"Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia","volume":"384","author":"Rosas","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2022.113499_bib236","first-page":"235","author":"Sparrow","year":"2017","journal-title":"Ther. antibodies Infect. Dis."},{"key":"10.1016\/j.biopha.2022.113499_bib237","first-page":"1","article-title":"Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012\/1: Matched cohort study","volume":"372","author":"Challen","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.biopha.2022.113499_bib238","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11908-021-00752-3","article-title":"Status Report on COVID-19 Vaccines Development","volume":"23","author":"Kumar","year":"2021","journal-title":"Curr. Infect. Dis. Rep."},{"key":"10.1016\/j.biopha.2022.113499_bib239","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ijid.2021.11.040","article-title":"Emergence of new SARS-CoV-2 Variant of Concern Omicron (B.1.1.529) - highlights Africa\u2019s research capabilities, but exposes major knowledge gaps, inequities of vaccine distribution, inadequacies in global COVID-19 response and control efforts","volume":"114","author":"Petersen","year":"2022","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.biopha.2022.113499_bib240","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/sciimmunol.abj1750","article-title":"SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees","volume":"6","author":"Geers","year":"2021","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.biopha.2022.113499_bib241","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12985-021-01737-3","article-title":"Sequential immunization with SARS-CoV-2 RBD vaccine induces potent and broad neutralization against variants in mice","volume":"19","author":"Song","year":"2022","journal-title":"Virol. J."},{"key":"10.1016\/j.biopha.2022.113499_bib242","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13205-021-03076-0","article-title":"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review","volume":"12","author":"Simnani","year":"2022","journal-title":"3 Biotech"},{"issue":"2021","key":"10.1016\/j.biopha.2022.113499_bib243","first-page":"1353","article-title":"Membrane fusion and immune evasion by the spike protein of SARS-CoV-2 Delta variant","volume":"374","author":"Zhang","year":"1979","journal-title":"Science"},{"key":"10.1016\/j.biopha.2022.113499_bib244","first-page":"1","article-title":"mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant","author":"Garcia-Beltran","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2022.113499_bib245","doi-asserted-by":"crossref","unstructured":"B.J. Willett, J. Grove, O.A. Maclean, C. Wilkie, N. Logan, G. De Lorenzo, W. Furnon, S. Scott, M. Manali, A. Szemiel, S. Ashraf, The hyper-transmissible SARS-CoV-2 Omicron variant exhibits significant antigenic change, vaccine escape and a switch in cell entry mechanism, MedRxiv. (2022).","DOI":"10.1101\/2022.01.03.21268111"},{"key":"10.1016\/j.biopha.2022.113499_bib246","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/S0140-6736(22)00462-7","article-title":"Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study","volume":"399","author":"Nyberg","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2022.113499_bib247","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105252","article-title":"Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern","volume":"198","author":"Vangeel","year":"2022","journal-title":"Antivir. Res."},{"key":"10.1016\/j.biopha.2022.113499_bib248","series-title":"Features, Evaluation, and Treatment of Coronavirus (COVID-19). Statpearls [internet]","author":"Marco Cascella","year":"2022"},{"key":"10.1016\/j.biopha.2022.113499_bib249","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/s41422-022-00618-w","article-title":"SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination","volume":"32","author":"Li","year":"2022","journal-title":"Cell Res."},{"key":"10.1016\/j.biopha.2022.113499_bib250","series-title":"Coronavirus (COVID-19) update: FDA limits use of certain monoclonal antibodies to treat COVID-19 due to the Omicron variant","author":"Cavazzoni","year":"2022"},{"key":"10.1016\/j.biopha.2022.113499_bib251","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.00926-22","article-title":"Susceptibility of SARS-CoV-2 Omicron Variants to Therapeutic Monoclonal Antibodies: Systematic Review and Meta-analysis","author":"Tao","year":"2022","journal-title":"Microbiol. Spectr."},{"key":"10.1016\/j.biopha.2022.113499_bib252","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2021.652688","article-title":"Fluvoxamine: A Review of Its Mechanism of Action and Its Role in COVID-19","volume":"12","author":"Sukhatme","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2022.113499_bib253","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1016\/S2214-109X(21)00448-4","article-title":"Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial","volume":"10","author":"Reis","year":"2022","journal-title":"Lancet Glob. Health"},{"key":"10.1016\/j.biopha.2022.113499_bib254","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.euroneuro.2007.03.010","article-title":"Immunomodulatory effect of selective serotonin reuptake inhibitors (SSRIs) on human T lymphocyte function and gene expression","volume":"17","author":"Taler","year":"2007","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.biopha.2022.113499_bib255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2021.652688","article-title":"Fluvoxamine: A Review of Its Mechanism of Action and Its Role in COVID-19","volume":"12","author":"Sukhatme","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2022.113499_bib256","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2021.787261","article-title":"Low-Dose Fluvoxamine Modulates Endocytic Trafficking of SARS-CoV-2 Spike Protein: A Potential Mechanism for Anti-COVID-19 Protection by Antidepressants","volume":"12","author":"Glebov","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2022.113499_bib257","first-page":"E71","article-title":"Expanded umbilical cord mesenchymal stem cells (UC-MSCs) as a therapeutic strategy in managing critically ILL COVID-19 patients: The case for compassionate use","volume":"23","author":"Atluri","year":"2020","journal-title":"Pain. Physician"},{"key":"10.1016\/j.biopha.2022.113499_bib258","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1002\/sctm.21-0046","article-title":"Umbilical cord mesenchymal stromal cells as critical COVID-19 adjuvant therapy: A randomized controlled trial","volume":"10","author":"Dilogo","year":"2021","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.biopha.2022.113499_bib259","doi-asserted-by":"crossref","DOI":"10.1002\/jcph.2067","article-title":"New Variants of SARS-CoV-2 and Next Generation of COVID-19 Treatments","author":"Khiali","year":"2022","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.biopha.2022.113499_bib260","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-28113-1","article-title":"A dual mechanism of action of AT-527 against SARS-CoV-2 polymerase","volume":"13","author":"Shannon","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2022.113499_bib261","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02479-20","article-title":"AT-527, a double prodrug of a guanosine nucleotide analog, is a potent inhibitor of SARS-CoV-2 in vitro and a promising oral antiviral for treatment of covid-19","volume":"65","author":"Good","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.biopha.2022.113499_bib262","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105270","article-title":"Unraveling the antiviral activity of plitidepsin against SARS-CoV-2 by subcellular and morphological analysis","volume":"200","author":"Sachse","year":"2022","journal-title":"Antivir. Res."},{"key":"10.1016\/j.biopha.2022.113499_bib263","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.202101200","article-title":"Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19","volume":"5","author":"Varona","year":"2022","journal-title":"Life Sci. Alliance"},{"key":"10.1016\/j.biopha.2022.113499_bib264","unstructured":"K.M. White, R. Rosales, S. Yildiz, T. Kehrer, L. Miorin, E. Moreno, S. Jangra, M.B. Uccellini, R. Rathnasinghe, L. Coughlan, C. Martinez-Romero, J. Batra, A. Rojc, M. Bouhaddou, J.M. Fabius, K. Obernier, M. Dejosez, M.J. Guill\u00e9n, A. Losada, P. Avil\u00e9s, M. Schotsaert, T. Zwaka, M. Vignuzzi, K.M. Shokat, N.J. Krogan, A. Garc\u00eda-Sastre, Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A, n.d. https:\/\/www.science.org."},{"key":"10.1016\/j.biopha.2022.113499_bib265","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.3390\/pharmaceutics13111759","article-title":"A comprehensive review about the molecular structure of severe acute respiratory syndrome coronavirus 2 (Sars-cov-2): Insights into natural products against covid-19","volume":"13","author":"Saied","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2022.113499_bib266","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12985-021-01624-x","article-title":"Keep out! SARS-CoV-2 entry inhibitors: their role and utility as COVID-19 therapeutics","volume":"18","author":"Chitsike","year":"2021","journal-title":"Virol. J."},{"key":"10.1016\/j.biopha.2022.113499_bib267","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.05.042","article-title":"SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract","volume":"182","author":"Hou","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2022.113499_bib268","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/ncb2210","article-title":"MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins","volume":"13","author":"Vickers","year":"2011","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.biopha.2022.113499_bib269","doi-asserted-by":"crossref","DOI":"10.1016\/j.virusres.2021.198631","article-title":"The role of microRNAs in solving COVID-19 puzzle from infection to therapeutics: A mini-review","volume":"308","author":"Paul","year":"2022","journal-title":"Virus Res."},{"key":"10.1016\/j.biopha.2022.113499_bib270","first-page":"226","article-title":"New strategies for treatment of COVID-19 and evolution of SARS-CoV-2 according to biodiversity and evolution theory","volume":"7","author":"Hassab Elnabi","year":"2020","journal-title":"Egypt. J. Basic Appl. Sci."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222008885?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222008885?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T11:58:32Z","timestamp":1779969512000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332222008885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":270,"alternative-id":["S0753332222008885"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2022.113499","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A comprehensive insight into current control of COVID-19: Immunogenicity, vaccination, and treatment.","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2022.113499","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"113499"}}